Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUL 6 ... organs delivered by yttrium-90 (Y-90) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous ...
2009 NOV 2 ... Research, "This paper presents a three-dimensional patient-specific simulation of carmustine delivery to brain tumor. The simulation investigates several crucial factors, ...
2009 FEB 23 ... different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.
The market ...
2009 OCT 5 ... significantly elevated risks were seen for doxorubicin, dactinomycin, dacarbazine, and carmustine. Results confirm the radiation sensitivity of the breast in girls age 10 to 20 years but ...
2009 MAR 23 ... in Tubingen, Germany report.
"The most commonly used regimens are carmustine (BCNU) monotherapy or lomustine (CCNU) combined with procarbazine and vincristine (PCV). ...
2009 AUG 24 ... and a combined chemotherapy treatment with Cisplatin (CDDP) (100 mg/sqm on day 1) and carmustine (BCNU) (160 mg/sqm on day 2); the treatment was repeated every 6 weeks for five cycles. ...
2009 NOV 1 ... different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors. The market ...
2009 JUL 6 ... to either erlotinib or a control arm that received treatment with either temozolomide or carmustine (BCNU). The primary end point was 6-month progression-free survival (PFS). Tumor ...
2009 MAR 16 ... lymphoma (NHL), Hodgkin's disease (HD) and multiple myeloma (MM), conditioned with carmustine, etoposide, cytarabine, melphalan or melphalan and transplanted with PBSC, were analyzed ...
2009 MAR 30 ... Group 2: PTV2 >= 75 cm(3)). Four RT dose levels were evaluated: 66,72,78, and 84 Gy. Carmustine 80 mg/m(2) was given during RT, then every 8 weeks for 6 cycles. Pretreatment ...
2009 MAR 9 ... out to evaluate the effect of exogenously administered metallothionein (MT) against carmustine (BCNU)-induced lung toxicity in rats. A total of 60 rats were randomly divided into four ...
2009 AUG 24 ... cellular sensitivity to melphalan not at all; to decarbazine, thiotepa, busulfan and carmustine moderately (1.2- to 2.4-fold); and to streptozotocin and temozolomide significantly ...
2009 APR 13 ... RIC regimens. However, only 32% agreed or strongly agreed that the combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) should be considered a RIC regimen. These ...
2009 AUG 31 ... used in the treatment of cancer--amifostine, fludarabine, dacarbazine, lomustine, carmustine and clofarabine--with seven additional drugs in late stage preclinical and early ...
2009 APR 20 ... USA.
Keywords: United States, New York, Brain Cancer, Brain Carcinoma, Carmustine, Chemotherapy, DNA, Dietary Supplement, Drug Development, Drug Resistance, Drug Therapy, ...
2009 NOV 23 ... and neurocognitive function). with supratentorial GBM were treated with a combination of carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy, respectively). Quality ...
